Long-read sequencing is a class of DNA sequencing technique and is also known the third-generation sequencing. It aids in overcoming and coping with throughput, scope, and accuracy application limits in genomics. In comparison to short-read sequencing, it has a variety of benefits such as short-read sequencing can only create up to 600 bases of DNA, while as long read sequencing technology may produce reads of more than 10,000 bases. Extensive application of this technological environment is expected to result in an improvement in comprehension of evolution of pathogens, cancer, genetic variety, and drug resistance in intricate sections of genome that are crucial for clinical care.
Major factors that drive growth of the global long read sequencing market include rise in utilization of sequence analysis methodologies and surge in demand for genome mapping program. In addition, increase in investments by key players toward R&D related to long-read sequencing technologies and rise in prevalence of genetic disorders and chronic diseases such as cancer further propel the market growth. However, lack of skilled professionals, and ethical and legal limitations are expected to restrain growth of the long-read sequencing market during the forecast period. In addition, nanopore sequencer has a lower read accuracy when compared to short read sequencers, which further hampers growth of the market. Conversely, use of cloud computing as a potential data management service and high growth potential in untapped emerging countries are anticipated to provide lucrative opportunities among the market players.
The long-read sequencing market is segmented on the basis of technology, product, application, end user, and region. By technique, the market is categorized into single-molecule real-time sequencing (SMRT), nanopore sequencing, and others. On the basis of product, it is segmented into instruments, consumables, and services. By application, it is bifurcated into clinical application and research application. By end user, it is segregated into academic & government research institutes, pharmaceutical & biotechnological companies, hospitals & clinics, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Major companies profiled in the report include Agilent Technologies, Inc. BaseClear BV, Cantata Bio, F. Hoffmann-La Roche Ltd., Future Genomics Technologies, The Genome Transcription Facility of Bordeaux, Grandomics, Jiangsu Hengrui Pharmaceutical Co.Ltd., MicrobesNG, Novogene, Oxford Nanopore Technologies, Pacific Biosciences Inc., St Vincent's Hospital Australia, Takara Holdings Inc., Thermo Fisher Scientific, Inc., Element Biosciences, and Illumina, Inc.
Major factors that drive growth of the global long read sequencing market include rise in utilization of sequence analysis methodologies and surge in demand for genome mapping program. In addition, increase in investments by key players toward R&D related to long-read sequencing technologies and rise in prevalence of genetic disorders and chronic diseases such as cancer further propel the market growth. However, lack of skilled professionals, and ethical and legal limitations are expected to restrain growth of the long-read sequencing market during the forecast period. In addition, nanopore sequencer has a lower read accuracy when compared to short read sequencers, which further hampers growth of the market. Conversely, use of cloud computing as a potential data management service and high growth potential in untapped emerging countries are anticipated to provide lucrative opportunities among the market players.
The long-read sequencing market is segmented on the basis of technology, product, application, end user, and region. By technique, the market is categorized into single-molecule real-time sequencing (SMRT), nanopore sequencing, and others. On the basis of product, it is segmented into instruments, consumables, and services. By application, it is bifurcated into clinical application and research application. By end user, it is segregated into academic & government research institutes, pharmaceutical & biotechnological companies, hospitals & clinics, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Major companies profiled in the report include Agilent Technologies, Inc. BaseClear BV, Cantata Bio, F. Hoffmann-La Roche Ltd., Future Genomics Technologies, The Genome Transcription Facility of Bordeaux, Grandomics, Jiangsu Hengrui Pharmaceutical Co.Ltd., MicrobesNG, Novogene, Oxford Nanopore Technologies, Pacific Biosciences Inc., St Vincent's Hospital Australia, Takara Holdings Inc., Thermo Fisher Scientific, Inc., Element Biosciences, and Illumina, Inc.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the long read sequencing market analysis from 2021 to 2031 to identify the prevailing long read sequencing market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the long read sequencing market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global long read sequencing market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Application
- Research Applications
- Clinical Applications
By Techniques
- Single-Molecule Real-Time Sequencing
- Nanopore Sequencing
- Others
By Product
- Instruments
- Type
- System
- Software
- Consumables
- Services
By End User
- Academic and Government Research Institutes
- Pharmaceutical and Biotech Companies
- Hospitals and Clinics
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Agilent Technologies
- BaseClear B.V
- Cantata Bio
- Element bioscience
- F. Hoffmann-La Roche Ltd
- Future Genomics Technologies B.V
- Genome Transcriptome Facility of Bordeaux
- GrandOmics
- JIANGSU HENFRUI PHARMACEUTICALS CO.LTD
- llumina, Inc
- MicrobesNG
- NOVOGENE
- Oxford Nanopore Technologies Limited
- Pacific Biosciences of California, Inc
- Takara Bio, Inc
- Thermo Fisher Scientific, Inc.
- St Vincents Hospital Austrailia
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: LONG READ SEQUENCING MARKET, BY TECHNIQUES
CHAPTER 5: LONG READ SEQUENCING MARKET, BY PRODUCT
CHAPTER 6: LONG READ SEQUENCING MARKET, BY APPLICATION
CHAPTER 7: LONG READ SEQUENCING MARKET, BY END USER
CHAPTER 8: LONG READ SEQUENCING MARKET, BY REGION
CHAPTER 9: COMPANY LANDSCAPE
CHAPTER 10: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to the report, titled, “Long Read Sequencing Market," the long read sequencing market was valued at $603.48 million in 2021, and is estimated to reach $4.5 billion by 2031, growing at a CAGR of 22.3% from 2022 to 2031.Long-read sequencing technologies are capable of reading longer lengths, between 5,000 and 30,000 base pairs. Therefore, they immediately address one of the main challenges faced by short-read sequencing. There are two main long-read sequencing technologies that sequence a single molecule, removing amplification bias and producing an acceptable length to overlap a sequence for better sequence assembly on a zero mode move guide chip. Pacific Biosciences have developed a Single Molecule Real-Time (SMRT) sequencer that generates reads that can exceed 10,000 bases in less than two hours and Oxford Nanopore Technologies’ platform is capable of producing reads of up to 1 million base pairs.
Key factors that drive growth of the market include, increase in prevalence of chronic diseases and genetic disorders and initiatives taken by governments for large scale sequencing projects. In addition, rise in utilization of sequence analysis methodologies and surge in demand for genome mapping program are some long read sequencing market trends which further expected to boost the market growth during the forecast period. However, lack of skill professionals and ethical and legal limitations is expected to hamper market growth during the forecast period. Conversely, use of cloud computing as a potential data management service and high growth potential in untapped emerging countries are expected to provide numerous opportunities for the long read sequencing industry during the forecast period.
By technique, the single-molecule real-time sequencing (SMRT) segment dominated the market in 2021, and is expected to remain dominant during the forecast period. This is attributed to surge in number of applications of single-molecule real-time sequencing and advancements in technology. Moreover, rise in prevalence of genetic disorders, developments associated with single real-time sequencing platforms, and improvements related with reimbursement scenario drive growth of the single-molecule real-time sequencing (SMRT) segment. Other techniques such as synthetic long read sequencing and loop genomics is projected to exhibit the fastest market growth during the forecast period. This is attributed to increase in investments by key players toward R&D related to synthetic long-read sequencing technologies, coupled with rise in prevalence of genetic disorders. Moreover, rise in use of epigenetics for development of novel treatment methods is anticipated to fuel long read sequencing market growth.
Depending on product, the consumables segment dominated the long read sequencing market size in 2021, and is expected to remain dominant during the forecast period. In addition, this segment is projected to show fastest growth during the forecast period, owing to the advent of novel pre-sequencing products and kits for executing DNA fragmentation, target enrichment, and size selection, which are expected to fuel the consumable segment growth during the forecast period.
On the basis of application, the research application segment was the major revenue contributor in 2021, and is anticipated to continue this trend during the forecast period, owing to increase in investments by key players toward R&D related to long-read sequencing applications. On the other side, the clinical application segment is projected to exhibit fastest growth during forecast period. This is attributed to increase in prevalence of chronic disease and genetic disorders.
By end user, pharmaceutical & biotechnological companies segment dominated the market in 2021, and is expected to remain dominant during the forecast period, owing to increase in investments by pharmaceutical and biotech companies in sequence analysis research to understand complex pattern of drug resistance developed by microorganisms, oncology, & molecular aspects of cancer, and drug discovery. Furthermore, the academic & government research institutes segment is projected to show fastest growth during the forecast period, owing to collaboration of research organizations and research institutes with government bodies to bear the high cost of research.
Region wise, North America had the highest long read sequencing market share in 2021, and is expected to register a CAGR of 20.2% during the forecast period. This is attributed to factors such as availability of a robust informatics network, well-established regulations for approval, distribution of genomic testing products & services, and presence of key players such as Pacific Biosciences in the region. Asia-Pacific is projected to register highest CAGR of 25.3% during the forecast period, owing to rise in penetration of leading players in emerging markets in the region and growth in investments for development of advanced diagnostic methods.
Key Findings of the Study
- •On the basis of technique, the single-molecule real-time sequencing (SMRT) segment dominated the market in 2021, and is expected to continue this trend during the forecast period.
•On the basis of application, the research application segment dominated the market in 2021, and is expected to continue this trend during the forecast period.
•Depending on end user, pharmaceutical & biotechnological companies segment is projected to grow at a CAGR of 21.3% during the forecast period.
•Region wise, North America garnered the largest revenue share in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR 25.3% during the forecast period.
Companies Mentioned
- Agilent Technologies
- Baseclear B.V
- Cantata Bio
- Element Bioscience
- F. Hoffmann-La Roche Ltd
- Future Genomics Technologies B.V
- Genome Transcriptome Facility of Bordeaux
- Grandomics
- Jiangsu Henfrui Pharmaceuticals Co.Ltd
- Llumina, Inc
- Microbesng
- Novogene
- Oxford Nanopore Technologies Limited
- Pacific Biosciences of California, Inc
- Takara Bio, Inc
- Thermo Fisher Scientific, Inc.
- St Vincents Hospital Austrailia
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
